Odronextamab Gets Priority Review for Relapsed, Refractory F

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Related Keywords

United States , American , , American Society Of Hematology Annual Meeting , Drug Administration , Biologics License Application , American Society , Hematology Annual Meeting , New Horizons , Diffuse Largeb Cell , Lymphoma , Follicular Lymphoma , Non Hodgkin Lymphoma ,